IgG4骤升与复发:确定IgG4相关病中IgG4上升动力学的预测阈值
该队列研究纳入155例IgG4相关病患者,随访中位33个月,每3个月检测IgG4。单次IgG4水平无显著预测复发价值,而IgG4-Ratio(相邻两次检测倍数变化)>1.6为最佳阈值,可预测复发;对IgG4-Ratio>1.6者强化治疗可降低68.3%复发风险(HR 0.317,95%CI 0.102-0.988;P=0.048)。
要点
- 单次IgG4水平不能预测复发,应关注IgG4动态变化。
- IgG4-Ratio>1.6(约3个月内IgG4升高>60%)为预测复发的最佳阈值。
- 对IgG4骤升者强化治疗可显著降低复发风险。
核心结论
- 需要从依赖静态IgG4水平转向监测IgG4动态变化,IgG4-Ratio>1.6定义的IgG4骤升可预测多数血清阳性IgG4-RD患者的复发。
- 对出现IgG4骤升的患者进行强化治疗可降低复发风险。
研究设计与样本
- 本研究为队列研究,在中国人民解放军总医院开展,纳入2016年2月至2023年5月随访>6个月且≥3次IgG4测量的IgG4-RD患者,共155例,中位随访33个月,访视间隔3个月。
- 采用时依Cox回归模型,将单次IgG4水平和IgG4-Ratio(相邻访视倍数变化)按不同阈值二分为指标,预测第三次连续访视时的复发。
- 使用限制性立方样条(RCS)在校正混杂因素后确定最佳IgG4-Ratio阈值,并分析强化治疗后的无复发生存。
主要发现
- 155例患者中149例基线IgG4阳性;63.8%(95/149)患者IgG4恢复正常,其中61.1%(58/95)出现IgG4再阳性。
- 单次IgG4水平无论作为连续变量还是二分变量,对复发均无显著预测价值。
- IgG4-Ratio阈值>1.1-1.3和>1.6-1.8显著预测复发(P<0.05),RCS证实非线性剂量反应关系(P=0.008)。
- IgG4-Ratio>1.6被确定为预测复发的最佳阈值。
- 在45例IgG4-Ratio>1.6患者中,强化治疗使复发风险降低68.3%(HR 0.317,95%CI 0.102-0.988;P=0.048)。
关键数值与推荐
- IgG4-Ratio>1.6(即相邻两次检测中位间隔3个月时IgG4水平升高>60%)为预测复发的最佳阈值。
- IgG4-Ratio阈值>1.1-1.3和>1.6-1.8均显著预测复发(P<0.05)。
- RCS显示IgG4-Ratio与复发风险呈非线性剂量反应关系(P=0.008)。
临床怎么用
- 对血清阳性IgG4-RD患者应连续监测IgG4水平并计算IgG4-Ratio,而非仅依赖单次IgG4值。
- 当IgG4-Ratio>1.6提示IgG4骤升时,可考虑强化治疗以降低复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate longitudinal IgG4 dynamics in IgG4-related disease (IgG4-RD), identify the predictive value of IgG4 rising kinetics for relapse and evaluate outcomes of intensified treatment following IgG4 surge. METHODS: This cohort study was conducted at the Chinese PLA General Hospital from February 2016 to May 2023, including patients with >6 months of follow-up and ≥3 IgG4 measurements. Single-timepoint IgG4 level and IgG4-Ratio (sequential visit-to-visit fold-change) were dichotomized as binary indicators using variable thresholds to predict relapse assessed at a third consecutive visit in time-dependent Cox regression models. We used restricted cubic splines (RCS) to identify the optimal IgG4-Ratio threshold with adjustment for confounders. Subsequently, relapse-free survival after intensified treatment was analysed. RESULTS: Among 155 patients (median follow-up: 33 months; inter-visit interval: 3 months), 149 had baseline IgG4 positivity. IgG4 normalized in 63.8% (95/149) patients, of whom 61.1% (58/95) developed IgG4 re-positivity. Single-timepoint IgG4 level, whether as continuous or dichotomized variables, showed no significant predictive value for relapse. IgG4-Ratio thresholds >1.1-1.3 and >1.6-1.8 significantly predicted relapse (P < 0.05), with RCS confirming a nonlinear dose-response relationship (P = 0.008). IgG4-Ratio >1.6 was identified as the optimal threshold to predict relapses. Among 45 patients with IgG4-Ratio >1.6, intensified treatment reduced relapse risk by 68.3% (HR 0.317, 95% CI 0.102-0.988; P = 0.048). CONCLUSIONS: A paradigm shift from relying on static IgG4 levels to monitoring IgG4 dynamics is needed. The IgG4 surge defined as an IgG4-Ratio >1.6 (indicating a >60% increase in IgG4 levels between consecutive measurements taken at median 3-month intervals) predicts relapse in the majority of seropositive IgG4-RD patients. Intensified treatment in patients with IgG4 surge can reduce recurrence risk.
引用
- Wang Y, Guo Y, Lu M, et al. IgG4 surge and relapse: determining the predictive threshold for IgG4 rising kinetics in IgG4-related disease. Rheumatology (Oxford). 2026. PMID: 41761585. doi:10.1093/rheumatology/keag034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。